A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE
A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE
The study will assess the efficacy, safety, and immunogenicity of PF-06410293 and adalimumab in combination with methotrexate in subjects with moderately to severly active rheumatoid arthritis who have had an inadequate response to methotrexate.
In an additional optional portion of the study, during open label Treatment Period 3 (TP3), a subset of subjects used a Prefilled Pen (PFP) to administer up to 3 injections of their study treatment (PF-06410293) at home.
Inclusion Criteria:
Exclusion Criteria:
Fullerton, California 92835, United States
Gainesville, Florida 32607, United States
Voorhees Township, New Jersey 08043, United States
Anjo-shi, Aichi-ken 446-8602, Japan
Arequipa, Arequipa, 04020, Peru
Elblag, 82-300, Poland
Elblag, 82-300, Poland
Kursk, 305007, Russia
Moscow, 129327, Russia
Saint Petersburg, 190068, Russia
Cape Town, Western Cape 7405, South Africa
M. Kharkiv, 61176, Ukraine
M. Kyiv,, 04107, Ukraine
Vinnytsia, 21018, Ukraine
Zaporizhzhya, 69600, Ukraine
Basingstoke, Hampshire RG24 9NA, United Kingdom
Metropolitan Borough of Wirral, Merseyside CH49 5PE, United Kingdom
Bath, Somerset BA1 1RL, United Kingdom